Piper Sandler Keeps Neutral Rating on ProFrac Holding, Reduces Price Target to $5
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
- Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Analyst Views on ACDC
About ACDC
About the author
ProFrac Holding Corp. (ACDC) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Loss Report: ProFrac Holding Corp. reported a quarterly loss of $0.6 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.43, and a significant decline from a loss of $0.13 per share a year ago.
Revenue Performance: The company generated revenues of $403.1 million for the quarter, missing the consensus estimate by 0.58% and down from $575.3 million in the same quarter last year.
Stock Outlook: ProFrac's stock has underperformed, losing about 35.2% since the beginning of the year, and currently holds a Zacks Rank #5 (Strong Sell), indicating expectations of further underperformance in the near future.
Industry Context: The Oil and Gas - Field Services industry is currently ranked in the bottom 40% of Zacks industries, which may negatively impact ProFrac's stock performance, while another sector company, National Energy Services Reunited, is set to report its earnings soon.
Major Stocks Including Monday.Com, Metsera, and Profrac Holding Decline in Pre-Market Trading on Monday
U.S. Stock Futures: U.S. stock futures rose this morning, with Nasdaq futures increasing by approximately 1.5% on Monday.
Monday.Com Earnings: Shares of Monday.Com Ltd fell 2.6% in pre-market trading ahead of its quarterly earnings report, with analysts expecting earnings of 88 cents per share and revenue of $312.26 million.
Other Stocks Declining: Several stocks experienced declines in pre-market trading, including Metsera Inc, which dropped 15% after Pfizer's $10 billion acquisition deal, and Ionis Pharmaceuticals, which fell 11.5% following disappointing study results.
Market Overview: Other notable declines included Oscar Health Inc down 5.4%, Centene Corp down 4.8%, and Profrac Holding Corp down 2.8%, reflecting a generally negative trend among various stocks.
